CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Phase 2

Recruiting

• Conditions: Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Endometrioid Ovarian Cancer
• Interventions: Drug: TORL-1-23; Drug: Pegfilgrastim (drug)

• Registration Number: NCT06690775
• Lead Sponsor: TORL Biotherapeutics, LLC

Brief Summary

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-11-13
• Study First Submitted QC: 2024-11-13
• Study First Posted: 2024-11-15
• Study Start: 2024-11-20
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-17
• Last Update Posted: 2025-04-23
• Primary Completion: 2027-10
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 230

Inclusion Criteria

Participants are eligible to be included in the study only if all the following criteria apply:

1. Females ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the informed consent.

2. Participants must sign the informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

3. Disease Type:

   • Histologically or cytologically confirmed diagnosis of advanced (unresectable) or metastatic high grade serous ovarian, primary peritoneal (i.e, of primary origin), or fallopian tube cancer. High-grade endometrioid ovarian cancer is permitted for enrollment.
   • Participant's tumor must be positive for CLDN6 expression as defined by the CLDN6 reference laboratory assay. Tumor tissue will be required for submission for CLDN6 testing prior to Cycle 1 Day 1.
   • Participants must have platinum-resistant disease, defined as the following:
   • If participants received only 1 line of platinum-based therapy, they must have completed 4 or more cycles of platinum-containing therapy, must have achieved a CR or PR, and progressed >3 months but ≤6 months after the last dose of platinum.
   • Participants who have received more than 1 line of platinum- based therapy must have progressed on or within 6 months after the last dose of platinum.
   • NOTE: This should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression (per RECIST v1.1).
   • Participants who are platinum-refractory during front-line treatment are excluded.
   • Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single- agent therapy is appropriate as the next line of treatment. Study rules for evaluation of number of prior systemic lines of therapy:
   • Adjuvant ± neoadjuvant is considered one line of therapy
   • Maintenance therapy (eg, bevacizumab or PARP inhibitors) will be considered part of the preceding line of therapy (ie, not counted independently)
   • Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)
   • Hormonal therapy will not be counted as a separate line of therapy

4. Measurable disease, per RECIST v1.1

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

6. Adequate organ function, based on the following laboratory values:

   • ANC: ≥1,500/mcL

   • Platelets: ≥100,000/mcL without transfusion within 4 weeks of first dose

   • Hemoglobin: 9 g/dL with transfusion or EPO support up to 14 days before eligibility assessment

   • Measured or calculated creatinine clearance with a validated formula*: ≥30 mL/min

   • Serum total bilirubin: ≤1.5 X ULN (participants with known Gilbert disease or liver metastases who have serum bilirubin level ≤3×ULN may be enrolled

   • AST (SGOT) and ALT (SGPT): ≤3 X ULN (participants with active liver metastases who have ALT/AST ≤5 X ULN may be enrolled)

   • Albumin: ≥2.5 g/dL

   • ECG: 12-Lead ECG with normal tracing or non-clinically significant changes that do not require medical intervention and QTcF interval

     • 470 msec and without history of Torsades des Pointes or other symptomatic QTc abnormality.

7. Participants of childbearing potential must have a negative serum pregnancy test within 72 hours before starting study drug treatment. The serum pregnancy test must be negative for the participant to be eligible.

8. Participants must agree to use a highly effective birth control method from the time of the first study drug treatment through 7 months after the last study drug treatment, or be of nonchildbearing potential.

9. Participants must agree not to donate eggs from the first study drug treatment through 7 months after the last study drug treatment.

10. Participants must agree to not breastfeed from the first dose of study treatment through 90 days after the last dose of study treatment.

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

1. Has not recovered [recovery is defined as National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade ≤1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.

2. Participants with clear cell, mucinous, sarcomatous (including carcinosarcoma), mixed histology, or low-grade, borderline ovarian tumors or non-epithelial ovarian cancers.

3. Participants with primary platinum-refractory ovarian, primary peritoneal (i.e. of primary origin) or fallopian tube cancer, defined as disease that did not respond to or has progressed within 3 months of the last dose of first line platinum-containing chemotherapy.

4. Received prior chemotherapeutic, investigational, radiotherapy, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23. There is no waiting period required for stereotactic radiosurgery.

5. Prior treatment with a CLDN6-targeting agent or an MMAE-containing ADC.

6. Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded.

7. Grade 2 or greater peripheral neuropathy.

8. History of non-infectious pneumonitis/ILD within 6 months of first dose of study drug.

9. Participants must not be considered a high medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.

10. History of significant cardiac disease:

    1. Congestive heart failure >New York Heart Association class 2 within last year
    2. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
    3. Myocardial infarction less than 6 months before start of study drug
    4. Anti-arrhythmic therapy (beta blockers are permitted)
    5. Any unstable ischemic disease or untreated arrhythmia

11. Known history of myelodysplastic syndrome or acute myeloid leukemia.

12. History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. Participants with malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ of the breast are not excluded.

13. Uncontrolled infection; active, clinically serious infections (CTCAE Grade >2).

14. Participants with seizure disorder requiring medication.

15. Known hypersensitivity or intolerance to any of the study drugs, study drug classes, or excipients in the formulation.

16. History of having an allogeneic bone marrow or organ transplant.

17. Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator.

18. Participants who are taking any drugs that are strong inducers and/or strong inhibitors of CYP3A4 enzymes.

19. Participants who are taking any drugs that are inhibitors of P-glycoprotein.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1	Pegfilgrastim (drug)	Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
Cohort 2	Pegfilgrastim (drug)	Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
Cohort 3	Pegfilgrastim (drug)	Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
Cohort 1	TORL-1-23	Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
Cohort 2	TORL-1-23	Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
Cohort 3	TORL-1-23	Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.

Primary Outcome Measures

Name	Time	Method
To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced PROC expressing CLDN6	At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months	Objective Response Rate (ORR) per RECIST v1.1 by Blinded Independent Central Review (BICR)

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DOR)	At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months	To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by Blinded Independent Central Review (BICR) and investigator assessment
Objective Response Rate (ORR)	At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months	To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by investigator assessment
Progression-free Survival (PFS)	At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months	To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by Blinded Independent Central Review (BICR) and by investigator assessment
Overall Survival (OS)	From time of consent until death or completion of study (Study duration is approximately 40 months)	To assess additional efficacy outcome measures of TORL-1-23
Incidence and severity of AEs and clinical laboratory abnormalities per CTCAE v5.0	From informed consent until 30 days after the last dose of study treatment, approximately 24 months (each cycle is 21 days)	To assess the safety and tolerability of TORL-1-23
CA-125 response per Gynecological Cancer Intergroup (GCIG) criteria	At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months	To assess the pharmacodynamic effects of TORL-1-23

Trial Locations

Locations (17)

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States

Stephenson Cancer Center at the University of Oklahoma; 🇺🇸 Oklahoma City, Oklahoma, United States

SCRI - Arizona Oncology Associates, PC-HOPE; 🇺🇸 Tucson, Arizona, United States

UCLA - JCCC Clinical Research Unit; 🇺🇸 Los Angeles, California, United States

SCRI - Sansum Clinic; 🇺🇸 Santa Barbara, California, United States

SCRI - Maryland Oncology Hematology, P.A.; 🇺🇸 Annapolis, Maryland, United States

SCRI - Minnesota Oncology Hematology, P.A.; 🇺🇸 Minneapolis, Minnesota, United States

SCRI - Northwest Cancer Specialists, P.C.; 🇺🇸 Portland, Oregon, United States

SCRI - Alliance Cancer Specialists, PC; 🇺🇸 Doylestown, Pennsylvania, United States

SCRI - Texas Oncology; 🇺🇸 Fort Worth, Texas, United States

SCRI - Virginia Oncology Associates; 🇺🇸 Norfolk, Virginia, United States

British Columbia Cancer Agency (BC Cancer, part of the Provincial Health Services Authority); 🇨🇦 Vancouver, British Columbia, Canada

Sunnybrook Health Sciences Centre; 🇨🇦 Toronto, Ontario, Canada

Princess Margaret Cancer Centre - University Health Network (UHN); 🇨🇦 Toronto, Ontario, Canada

Centre Hospitalier de l'Universite de Montreal (CHUM); 🇨🇦 Montreal, Quebec, Canada

Sir Mortimer B. Davis Jewish General Hospital; 🇨🇦 Montreal, Quebec, Canada

McGill University Health Centre (MUHC) - Royal Victoria Hospital; 🇨🇦 Montreal, Quebec, Canada